Back to search results

Assessing Fallopian Tube Blockage During Fibroid Surgery

This study is looking at how uterine fibroids and their surgical removal (myomectomy) might affect the fallopian tubes. Researchers will use a procedure called chromopertubation, which involves injecting a blue dye (methylene blue) into the uterus, to see if your fallopian tubes are open or blocked before and after your fibroid surgery. This helps them understand if fibroids or the surgery itself can cause blockages that might affect fertility. The main goal is to see how often fallopian tubes are blocked before and after myomectomy. You may be able to join if you are a woman aged 18 or older, having minimally invasive fibroid removal surgery at MedStar, and meet other specific criteria. The study aims to enroll 50 participants.

Study design
This is an interventional study with an estimated enrollment of 50 women. It is not specified if it is randomized or blinded.
What's involved
You would undergo the chromopertubation procedure before and after your myomectomy surgery, all within the duration of each surgery.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured only during the duration of each surgery, so no long-term follow-up is specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06988774

Assessment of Tubal Occlusion During Minimally Invasive Myomectomy

Recruiting
NAAges 18+InterventionalDiagnostic
Medstar Health Research Institute
~50 participants
Updated 2025-06-29 on ClinicalTrials.gov
What's tested:chromopertubation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequency of tubal occlusion pre- and post-myomectomy
Measured over Limited to the duration of each surgery

Conditions

Fallopian Tube Patency Tests
Fibroid/Myoma (Uterus/Cervix)
Myomectomy
Fallopian Tube Disease

Explore related trials

Uterine Corpus Leiomyoma

NCT06988774

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Alexandra Snyder, MD
[email protected]
202-877-6526
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients undergoing minimally invasive laparoscopic or robotic-assisted uterine-preserving gynecologic surgery for removal of uterine fibroids (myomectomy) by a minimally invasive gynecologic surgeon at MedStar.

Exclusion

Patients with both fallopian tubes absent
Patients in whom it is not possible to place a uterine manipulator or catheter
Patient with known tubal disease or occlusion, or patients who have undergone prior tubal surgery
Patients with allergy to methylene blue dye or G6PD deficiency
Patients with positive pregnancy test on day of surgery

What this trial measures

  • Frequency of tubal occlusion pre- and post-myomectomyLimited to the duration of each surgery

    Frequency of tubal occlusion in patients with fibroids immediately prior to and after completion of myomectomy procedures. Spillage of methylene blue dye seen laparoscopically is indicative of tubal patency. Unilateral vs bilateral occlusion will be documented.